<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988545</url>
  </required_header>
  <id_info>
    <org_study_id>2013.GLP-1</org_study_id>
    <nct_id>NCT01988545</nct_id>
  </id_info>
  <brief_title>GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow</brief_title>
  <official_title>GLP-1's Influence on Intestinal Blood Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Koge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Koge</source>
  <oversight_info>
    <authority>Denmark: The Ministry of the Interior and Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and
      cardiac parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and
      cardiac parameters, in healthy subjects, 4 arms, task force monitor
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>blood flow</measure>
    <time_frame>with in 120 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood flow change measured by ultra sound</description>
  </primary_outcome>
  <other_outcome>
    <measure>cardiac parameters</measure>
    <time_frame>with in 120 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure of cardiac change with task force monitor</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,5 nmol/kg,GLP-1 sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 9-36amide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,5 nmol/kg GLP-1 9-36amide, sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exendin-4 ;10 ug,sc injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 ml of isotonic saline, sc injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1,5 nmol/kg,GLP-1 sc injection</intervention_name>
    <arm_group_label>GLP-1 9-36amide</arm_group_label>
    <arm_group_label>Exendin-4</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
    <other_name>native GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1,5 nmol/kg GLP-1 9-36amide, sc injection</intervention_name>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_label>Exendin-4</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
    <other_name>1,5 nmol/kg GLP-1 9-36amide, sc injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exendin-4 ;10 ug,sc injection</intervention_name>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_label>GLP-1 9-36amide</arm_group_label>
    <other_name>Exendin-4 ;10 ug,sc injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subjects

        Exclusion Criteria:

          -  medical conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lasse Bremholm, MD, ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Køge Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lasse Bremholm, MD, ph.d.</last_name>
    <phone>0004560927874</phone>
    <email>lassebremholm@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Køge Hospital</name>
      <address>
        <city>Køge</city>
        <state>State...</state>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lasse bremholm, MD, ph.d.</last_name>
      <phone>004560927874</phone>
      <email>lassebremholm@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Lasse Bremholm, MD, ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Koge</investigator_affiliation>
    <investigator_full_name>MD ph.d. Lasse Bremholm</investigator_full_name>
    <investigator_title>MD, ass. professor, ph.d</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>blood flow</keyword>
  <keyword>cardiac out put</keyword>
  <keyword>stroke volume</keyword>
  <keyword>beat to beat</keyword>
  <keyword>effect of GLP-1 on cardiac parameters and blood flow</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
